| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Transplantation Research Center, Brigham and Women’s Hospital and Children’s Hospital, Boston, Harvard Medical School, Boston, MA 02115;
Department of Medicine, Division of Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115;
Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan;
Department of Molecular Immunology, Tokyo Medical and Dental University, Tokyo, Japan; and
¶ Department of Medicine, Renal Division, University of Pennsylvania, Philadelphia, PA 19104
Programmed death-1 (PD-1), an inhibitory receptor up-regulated on activated T cells, has been shown to play a critical immunoregulatory role in peripheral tolerance, but its role in alloimmune responses is poorly understood. Using a novel alloreactive TCR-transgenic model system, we examined the functions of this pathway in the regulation of alloreactive CD4+ T cell responses in vivo. PD-L1, but not PD-1 or PD-L2, blockade accelerated MHC class II-mismatched skin graft (bm12 (I-Abm12) into B6 (I-Ab)) rejection in a similar manner to CTLA-4 blockade. In an adoptive transfer model system using the recently described anti-bm12 (ABM) TCR-transgenic mice directly reactive to I-Abm12, PD-1 and PD-L1 blockade enhanced T cell proliferation early in the immune response. In contrast, at a later time point preceding accelerated allograft rejection, only PD-L1 blockade enhanced T cell proliferation. In addition, PD-L1 blockade enhanced alloreactive Th1 cell differentiation. Apoptosis of alloantigen-specific T cells was inhibited significantly by PD-L1 but not PD-1 blockade, indicating that PD-1 may not be the receptor for the apoptotic effect of the PD-L1-signaling pathway. Interestingly, the effect of PD-L1 blockade was dependent on the presence of CD4+CD25+ regulatory T cells in vivo. These data demonstrate a critical role for the PD-1 pathway, particularly PD-1/PD-L1 interactions, in the regulation of alloimmune responses in vivo.
This article has been cited by other articles:
|
|
 |
|
  B. H. Koehn, M. L. Ford, I. R. Ferrer, K. Borom, S. Gangappa, A. D. Kirk, and C. P. Larsen PD-1-Dependent Mechanisms Maintain Peripheral Tolerance of Donor-Reactive CD8+ T Cells to Transplanted Tissue J. Immunol., October 15, 2008; 181(8): 5313 - 5322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-J. Wang, F.-C. Chou, C.-H. Chu, J.-C. Wu, S.-H. Lin, D.-M. Chang, and H.-K. Sytwu Protective Role of Programmed Death 1 Ligand 1 (PD-L1)in Nonobese Diabetic Mice: The Paradox in Transgenic Models Diabetes, July 1, 2008; 57(7): 1861 - 1869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yang, J. Popoola, S. Khandwala, N. Vadivel, V. Vanguri, X. Yuan, S. Dada, I. Guleria, C. Tian, M. J. Ansari, et al. Critical Role of Donor Tissue Expression of Programmed Death Ligand-1 in Regulating Cardiac Allograft Rejection and Vasculopathy Circulation, February 5, 2008; 117(5): 660 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Giorgini and A. Noble Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts J. Leukoc. Biol., November 1, 2007; 82(5): 1053 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tanaka, M. J. Albin, X. Yuan, K. Yamaura, A. Habicht, T. Murayama, M. Grimm, A. M. Waaga, T. Ueno, R. F. Padera, et al. PDL1 Is Required for Peripheral Transplantation Tolerance and Protection from Chronic Allograft Rejection J. Immunol., October 15, 2007; 179(8): 5204 - 5210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Habicht, S. Dada, M. Jurewicz, B. T. Fife, H. Yagita, M. Azuma, M. H. Sayegh, and I. Guleria A Link between PDL1 and T Regulatory Cells in Fetomaternal Tolerance J. Immunol., October 15, 2007; 179(8): 5211 - 5219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Izawa, K. Yamaura, M. J. Albin, M. Jurewicz, K. Tanaka, M. R. Clarkson, T. Ueno, A. Habicht, G. J. Freeman, H. Yagita, et al. A Novel Alloantigen-Specific CD8+PD1+ Regulatory T Cell Induced by ICOS-B7h Blockade In Vivo J. Immunol., July 15, 2007; 179(2): 786 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Waeckerle-Men, A. Starke, and R. P. Wuthrich PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+cytotoxic T cells Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1527 - 1536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Guleria and M. H. Sayegh Maternal Acceptance of the Fetus: True Human Tolerance J. Immunol., March 15, 2007; 178(6): 3345 - 3351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Hillebrands, B. Whalen, J. T. J. Visser, J. Koning, K. D. Bishop, J. Leif, J. Rozing, J. P. Mordes, D. L. Greiner, and A. A. Rossini A Regulatory CD4+ T Cell Subset in the BB Rat Model of Autoimmune Diabetes Expresses Neither CD25 Nor Foxp3 J. Immunol., December 1, 2006; 177(11): 7820 - 7832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Meng, P. Yang, B. Li, H. Zhou, X. Huang, L. Zhu, Y. Ren, and A. Kijlstra CD4+PD-1+ T Cells Acting as Regulatory Cells during the Induction of Anterior Chamber-Associated Immune Deviation. Invest. Ophthalmol. Vis. Sci., October 1, 2006; 47(10): 4444 - 4452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zhu, I. Guleria, A. Khosroshahi, T. Chitnis, J. Imitola, M. Azuma, H. Yagita, M. H. Sayegh, and S. J. Khoury Differential Role of Programmed Death-Ligand 1 and Programmed Death-Ligand 2 in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis J. Immunol., March 15, 2006; 176(6): 3480 - 3489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Raimondi, W. J. Shufesky, D. Tokita, A. E. Morelli, and A. W. Thomson Regulated Compartmentalization of Programmed Cell Death-1 Discriminates CD4+CD25+ Resting Regulatory T Cells from Activated T Cells. J. Immunol., March 1, 2006; 176(5): 2808 - 2816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Habicht, M. R. Clarkson, J. Yang, J. Henderson, V. Brinkmann, S. Fernandes, M. Jurewicz, X. Yuan, and M. H. Sayegh Novel Insights into the Mechanism of Action of FTY720 in a Transgenic Model of Allograft Rejection: Implications for Therapy of Chronic Rejection J. Immunol., January 1, 2006; 176(1): 36 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tao, L. Wang, R. Han, T. Wang, Q. Ye, T. Honjo, T. L. Murphy, K. M. Murphy, and W. W. Hancock Differential Effects of B and T Lymphocyte Attenuator and Programmed Death-1 on Acceptance of Partially versus Fully MHC-Mismatched Cardiac Allografts J. Immunol., November 1, 2005; 175(9): 5774 - 5782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Guleria, A. Khosroshahi, M. J. Ansari, A. Habicht, M. Azuma, H. Yagita, R. J. Noelle, A. Coyle, A. L. Mellor, S. J. Khoury, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance J. Exp. Med., July 18, 2005; 202(2): 231 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ito, T. Ueno, M. R. Clarkson, X. Yuan, M. M. Jurewicz, H. Yagita, M. Azuma, A. H. Sharpe, H. Auchincloss Jr, M. H. Sayegh, et al. Analysis of the Role of Negative T Cell Costimulatory Pathways in CD4 and CD8 T Cell-Mediated Alloimmune Responses In Vivo J. Immunol., June 1, 2005; 174(11): 6648 - 6656. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
